Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stock, Common [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Consolidation Items [Axis]
Operating Segments [Member]
Segments [Axis]
Clinical Research [Member]
Subsegments [Axis]
OVATION 2 and MRD Trials [Member]
Ovation Three [Member]
Placcine Vaccine [Member]
Other Clinical and Regulatory [Member]
Non-Clinical R&D and CMC [Member]
Ovation [Member]
Manufacturing (CMC) [Member]
Statistical Measurement [Axis]
Maximum [Member]
Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
At the Market Offering Agreement [Member]
Statement of Income Location, Balance [Axis]
Sales Agreement [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Securities Purchase Agreement [Member]
Sale of Stock [Axis]
July 2024 Offering [Member]
Warrant [Member]
May 2025 Offering [Member]
Pre Funded [Member]
Placement Agents Warrant [Member]
Plan Name [Axis]
2018 Stock Incentive Plan [Member]
Award Type [Axis]
Equity Stock Awards [Member]
Scenario [Axis]
Granted Under 2018 Plan and 2007 Plan [Member]
2018 Plan [Member]
Stock Options and Restricted Stock Awards [Member]
Research and Development Expense [Member]
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Option [Member]
Restricted Stock [Member]
Lawrenceville New Jersey Lease [Member]
Forecast [Member]
Huntsville Alabama Lease [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Entity Information, Former Legal or Registered Name
Entity Listing, Par Value Per Share
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash and cash equivalents
Advances and deposits on clinical programs and other current assets
Total current assets
Property and equipment (at cost, less accumulated depreciation and amortization)
Other assets:
Operating lease right-of-use assets, net
Deposits and other assets
Total other assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable – trade
Other accrued liabilities
Operating lease liabilities - current portion
Total current liabilities
Operating lease liabilities - non-current portion
Total liabilities
Commitments and contingencies
Stockholders’ equity:
Preferred stock - $0.01 par value (100,000 shares authorized and no shares issued or outstanding at September 30, 2025 and December 31, 2024)
Common stock - $0.01 par value (350,000,000 and 112,500,000 shares authorized at September 30, 2025 and December 31, 2024, respectively); 2,896,275 and 966,714 shares issued at September 30, 2025 and December 31, 2024, respectively; and 2,896,273 and 966,712 shares outstanding at September 30, 2025 and December 31, 2024, respectively)
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity before treasury stock
Treasury stock, at cost (2 shares at September 30, 2025 and December 31, 2024)
Total stockholders’ equity
Total liabilities and stockholders’ equity
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Treasury stock, shares
Income Statement [Abstract]
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income:
Investment income, net
Total other income, net
Net loss
Net loss per common share
Basic
Diluted
Weighted average shares outstanding
Basic
Diluted
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization of right-of-use assets
Realized losses, net, on investment securities
Stock-based compensation
Shares issued in exchange for services
Realization of deferred income tax asset
Net changes in:
Advances, deposits, and other current assets
Accounts payable and accrued liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchases of investment securities
Proceeds from sale and maturity of investment securities
Purchases of property and equipment
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Proceeds from sale of common stock equity, net of issuance costs
Proceeds from issuance of common stock upon exercise of warrants
Issuance costs for stock dividend
Net cash provided by financing activities
Net change in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalent at end of period
Supplemental disclosures of cash flow information:
Non-cash investing and financing activities:
Recognition of operating lease right-of-use asset and liability
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Balance, shares
Effect of reverse stock split
Effect of reverse stock split, shares
Sale of equity through equity financing facilities, net of issuance costs
Sale of equity through equity financing facilities, net of issuance costs, shares
Issuance of common stock upon exercise of common stock warrants
Issuance of common stock upon exercise of common stock warrants, shares
Stock dividend, net of offering costs
Stock dividend, net of offering costs, shares
Shares issued to satisfy certain obligations
Shares issued to satisfy certain obligations, shares
Issuance of common stock upon exercise of restricted options
Issuance of common stock upon exercise of restricted options, shares
Stock-based compensation expense
Realized and unrealized losses, net, on investments securities
Realized and unrealized gains (losses), net, on investments securities, shares
Balance
Balance, shares
Balance, shares
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Non-Rule 10b5-1 Arrangement Modified
Non-Rule 10b5-1 Arrangement Modified
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Accounting Policies [Abstract]
Business Description
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements
Earnings Per Share [Abstract]
Net Loss per Common Share
Segment Reporting [Abstract]
Segment Performance Measures and Expenses
Payables and Accruals [Abstract]
Other Accrued Liabilities
Equity [Abstract]
Stockholders’ Equity
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation
Warrants
Warrants
Leases
Leases
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Subsequent Events [Abstract]
Subsequent Events
Schedule of Significant Expense Categories and Consolidated Net Loss
Schedule of Other Accrued Liabilities
Schedule of Stock Options Awards and Restricted Stock Grants
Schedule of Assumptions Used to Determine Fair Value of Options Granted
Schedule of Warrant Activity
Schedule of Lease Payments and Maturity of Operating Lease Liabilities
Net loss
Cash to fund operation
Cumulative net loss
Cash and cash equivalents, short-term investments, and interest receivable
Anti-dilutive securities
Stock dividend percentage
Schedule of Segment Reporting Information, by Segment [Table]
Segment Reporting Information [Line Items]
Subtotal
Change Increase (Decrease), Research and development expenses
Change Increase (Decrease), Subtotal, percentage
Research and development expenses
Change Increase (Decrease), Research and development expenses, percentage
General and administrative expenses
Change Increase (Decrease), General and administrative expenses
Change Increase (Decrease), General and administrative expenses, percentage
Total operating expenses
Change Increase (Decrease), Operating expenses
Change Increase (Decrease), Operating expenses, percentage
Loss from operations
Change Increase (Decrease), Loss from operations
Change Increase (Decrease), Loss from operations, percentage
Number of operating segment
Number of reportable segment
Amounts due to contract research organizations and other contractual agreements
Accrued payroll and related benefits
Accrued professional fees and other
Total
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period, value, new issues
Stock issued, shares
Share price
Reverse stock split
Reverse stock split shares
Options outstanding
Stock awards reduced
Number of authorized shares of common stock
Stock dividend percentage
Dividend per share
Proceeds from issuance of common stock
Prospectus supplement covers aggregate shares
Remaining amount
Additional prospectus supplement amount
Number of shares sold
Proceeds from sale of stock
Common stock par value
Warrants outstanding
Common stock outstanding percentage
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding, beginning balance
Weighted average exercise price, beginning balance
Non-vested stock awards, beginning balance
Weighted average grant date fair value, beginning balance
Options outstanding, granted
Weighted average exercise price, granted
Non-vested stock awards, granted
Weighted average grant date fair value, granted
Options outstanding, issued
Weighted average exercise price, issued
Non-vested stock awards, issued
Weighted average grant date fair value, issued
Equity awards terminated or forfeited
Equity awards terminated or forfeited
Non-vested stock awards, Terminated
Weighted average grant date fair value, Terminated or forfeited
Options outstanding, ending balance
Weighted average exercise price, ending balance
Non-vested stock awards, ending balance
Weighted average grant date fair value, ending balance
Weighted average contractual terms
Options outstanding, exercisable
Weighted average exercise price, exercisable
Weighted average contractual terms, exercisable
Options outstanding, aggregate intrinsic value, exercisable
Risk-free interest rate, minimum
Risk-free interest rate, maximum
Expected volatility, minimum
Expected volatility, maximum
Expected life (in years)
Expected dividend yield
Number of shares authorized
Common stock, reserved for future issuance
Shares available for issuance
Number of shares common stock
Share based compensation
Unrecognized compensation cost
Cost recognized period
Weighted average grant date fair value per share
Schedule Of Warrant Activity
Number of Warrants Issued, Warrants outstanding, Beginning balance
Weighted Average Exercise Price, Warrants outstanding, Beginning balance
Number of Warrants Issued, Warrants issued
Weighted Average Exercise Price, Warrants issued
Number of Warrants Issued, Warrants exercised cashless
Weighted Average Exercise Price, Warrants exercised cashless
Number of Warrants Issued, Warrants exercised
Weighted Average Exercise Price, Warrants exercised
Number of Warrants Issued, Warrants expired
Weighted Average Exercise Price, Warrants expired
Number of Warrants Issued, Warrants outstanding, Ending balance
Weighted Average Exercise Price, Warrants outstanding, Ending balance
Aggregate intrinsic value of outstanding warrants
Weighted average remaining contractual terms
Lessee, Lease, Description [Table]
Lessee, Lease, Description [Line Items]
Operating lease, term
Area of land
Payments for rent
Operating lease, cost
Operating lease, payments
Schedule Of Lease Payments And Maturity Of Operating Lease Liabilities
2025
2026
2027
2028
Subtotal future lease payments
Less imputed interest
Total lease liabilities
Operating lease, weighted average remaining lease term
Operating lease, weighted average discount rate, percent
Non rule 10b51 arrmodified flag.
Rule 10b51 Arr Modified Flag
Recognition of right of use asset and liability.
Issuance of common stock upon exercise of common stock warrants.
Stock issued during period value reverse stock splits
Issuance of common stock upon exercise of warrants shares.
Stock issued during period value realized and unrealized gains loss.
Stock issued during period shares realized and unrealized gains loss.
Cumulative net income loss.
Clinical Research [Member]
OVATION 2 and MRD Trials [Member]
Ovation Three [Member]
Placcine Vaccine [Member]
Increase decrease in operating cost and expenses.
Ovation [Member]
Other Clinical and Regulatory [Member]
Non-Clinical R&D and CMC [Member]
Manufacturing (CMC) [Member]
Increase decrease in general and administrative expenes.
Increase decrease in operating expenses.
Increase decrease in loss from operations.
Increase decrease in operating costs and expenses percentage.
Increase decrease in research and development expenses percentage.
Increase decrease in general and administrative expenses percentage.
Increase decrease in operating expenses percentage.
Increase decrease in loss from operations percentage.
Options outstanding amount.
Stock awards reduced amount.
Stock dividend rate percentage.
Dividends common stock per share.
At the Market Offering Agreement [Member]
Sales Agreement [Member]
Aggregate shares.
Remaining share amount.
Additional prospectus supplement amount.
Securities Purchase Agreement [Member]
July 2024 Offering [Member]
Common stock outstanding percentage.
May 2025 Offering [Member]
Pre Funded [Member]
Placement Agents Warrant [Member]
2018 Stock Incentive Plan [Member]
Equity Stock Awards [Member]
Granted Under 2018 Plan and 2007 Plan [Member]
2018 Plan [Member]
Stock Options and Restricted Stock Awards [Member]
Summary of Stock Option and Restricted Stock Awards [Table Text Block]
Share based compensation arrangement by share based payment award options issued.
Share based compensation arrangement by share based payment award options issued weighted average exercise price per share.
Share based compensation arrangement by share based payment award other than options issued.
Share based compensation arrangement by share based payment award other than options issued grant date fair value.
Warrants [Text Block]
Weighted average price at which grantees can acquire the shares reserved for issuance under the non option equity instruments warrants exercised cashless.
Sharebased compensation arrangement by sharebased payment award non options outstanding intrinsic value.
Weighted average remaining contractual term for non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.
Weighted average price at which grantees can acquire the shares reserved for issuance under the weighted average exercise price warrants issued.
Weighted average price at which grantees can acquire the shares reserved for issuance under the weighted average exercise price warrants exercised cashless.
Weighted average price at which grantees can acquire the shares reserved for issuance under the weighted average exercise price warrants exercised.
Lawrenceville New Jersey Lease [Member]
Huntsville Alabama Lease [Member]
Lessee operating lease liability payments due after year four.
Stock issued during period value stock dividend net.
Stock issued during period shares stock dividend net.
Assets, Current
Other Assets, Noncurrent
Assets
Liabilities, Current
Liabilities
Stockholders' Equity before Treasury Stock
Treasury Stock, Value
Equity, Attributable to Parent
Liabilities and Equity
Nonoperating Income (Expense)
Weighted Average Number of Shares Outstanding, Basic
Weighted Average Number of Shares Outstanding, Diluted
Gain (Loss) on Investments
Increase (Decrease) in Other Current Assets
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Debt Securities, Available-for-Sale
Payments to Acquire Property, Plant, and Equipment
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Payments of Stock Issuance Costs
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Shares, Outstanding
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
NonRule10b51ArrModifiedFlag
Warrants [Text Block]
Lessee, Operating Leases [Text Block]
StockDividendRatePercentage
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount